MCID: PYR010
MIFTS: 54

Peyronie's Disease

Categories: Rare diseases, Reproductive diseases

Aliases & Classifications for Peyronie's Disease

MalaCards integrated aliases for Peyronie's Disease:

Name: Peyronie's Disease 41 12 15
Peyronie Disease 12 73
Balanitis Xerotica Obliterans 73
Induratio Penis Plastica 12
Peyronie's Fibromatosis 12
Peyronies Disease 41
Penile Induration 44

Classifications:



External Ids:

Disease Ontology 12 DOID:8616
ICD10 33 N48.6
ICD9CM 35 607.85
MeSH 44 D010411
NCIt 50 C3316
SNOMED-CT 68 1335005

Summaries for Peyronie's Disease

MalaCards based summary : Peyronie's Disease, also known as peyronie disease, is related to peyronie disease and dupuytren contracture. An important gene associated with Peyronie's Disease is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Acetylcholine and Chlorhexidine have been mentioned in the context of this disorder. Affiliated tissues include small intestine, bone and lung, and related phenotypes are cellular and craniofacial

Wikipedia : 76 Peyronie''s disease is a connective tissue disorder involving the growth of fibrous plaques in the soft... more...

Related Diseases for Peyronie's Disease

Diseases in the Peyronie Disease family:

Peyronie's Disease

Diseases related to Peyronie's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
# Related Disease Score Top Affiliating Genes
1 peyronie disease 34.0 IFNA2 TGFB1 TGFB3
2 dupuytren contracture 31.7 DCN TGFB1
3 ledderhose disease 11.1
4 impotence 10.2
5 giant hemangioma 10.2 IFNA2 TGFB1
6 cutaneous polyarteritis nodosa 10.2 IFNA2 SMAD3
7 polyarteritis nodosa 10.2 IFNA2 SMAD3
8 penile disease 10.2 IFNA2 TGFB1
9 stiff skin syndrome 10.1 TGFB1 TGFB2
10 multilocular clear cell renal cell carcinoma 10.1 TGFB2 TGFB3
11 diabetic foot ulcers 10.1 CCL2 TGFB1
12 ascending cholangitis 10.1 CCL2 TGFB1
13 loeys-dietz syndrome 3 10.1 SMAD3 TGFB2
14 hypertrophic scars 10.1 SMAD3 TGFB1 TGFB3
15 tuberculous meningitis 10.1 CCL2 TGFB1
16 vitreous disease 10.0 CCL2 TGFB2
17 tuberculoid leprosy 10.0 TGFB1 TGFB2 TGFB3
18 macular holes 10.0 CCL2 TGFB2
19 pustulosis palmaris et plantaris 10.0 SMAD7 TGFB1
20 loeys-dietz syndrome 10.0 SMAD3 TGFB2 TGFB3
21 loeys-dietz syndrome 4 10.0 SMAD3 TGFB2 TGFB3
22 localized scleroderma 10.0 DCN SMAD3 TGFB1
23 tendinosis 10.0 DCN TGFB2
24 nephrosclerosis 10.0 CCL2 TGFB1
25 vitreoretinopathy, neovascular inflammatory 10.0 CCL2 TGFB1 TGFB2
26 pulmonary fibrosis, idiopathic 10.0 CCL2 SMAD3 TGFB1
27 ureteral disease 10.0 SMAD3 SMAD7 TGFB1
28 uveitis 10.0 CCL2 IFNA2 TGFB2
29 hypochondrogenesis 9.9 SMAD3 SMAD7 TGFB3
30 bullous keratopathy 9.9 DCN TGFB2
31 loeys-dietz syndrome 1 9.9 SMAD3 TGFB2
32 sexual disorder 9.9
33 compartment syndrome 9.9
34 colitis 9.9 SMAD3 SMAD4 SMAD7
35 keloids 9.8 SMAD3 SMAD7 TGFB1 TGFB3
36 urinary tract obstruction 9.8 CCL2 SMAD3 SMAD7 TGFB1
37 renal fibrosis 9.8 CCL2 SMAD3 SMAD7 TGFB1
38 pulmonary fibrosis 9.8 CCL2 SMAD3 SMAD7 TGFB1
39 inflammatory bowel disease 9.7 CCL2 SMAD3 SMAD7 TGFB1
40 nephrogenic systemic fibrosis 9.6 DCN SMAD3 SMAD4 SMAD7 TGFB1
41 colorectal cancer 9.4 IFNA2 SMAD3 SMAD4 SMAD7 TGFB1 TGFB2

Comorbidity relations with Peyronie's Disease via Phenotypic Disease Network (PDN):


Bladder Neck Obstruction Prostatic Hypertrophy
Urethral Stricture

Graphical network of the top 20 diseases related to Peyronie's Disease:



Diseases related to Peyronie's Disease

Symptoms & Phenotypes for Peyronie's Disease

MGI Mouse Phenotypes related to Peyronie's Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 DCN SMAD3 SMAD4 SMAD7 TGFB1 TGFB2
2 craniofacial MP:0005382 10 DCN SMAD3 SMAD4 SMAD7 TGFB1 TGFB2
3 digestive/alimentary MP:0005381 9.98 DCN SMAD3 SMAD4 SMAD7 TGFB1 TGFB2
4 embryo MP:0005380 9.88 SMAD3 SMAD4 SMAD7 TGFB1 TGFB2 TGFB3
5 hematopoietic system MP:0005397 9.87 DCN SMAD3 SMAD4 SMAD7 TGFB1 TGFB2
6 immune system MP:0005387 9.86 CCL2 DCN SMAD3 SMAD4 SMAD7 TGFB1
7 endocrine/exocrine gland MP:0005379 9.85 DCN SMAD3 SMAD4 SMAD7 TGFB1 TGFB2
8 renal/urinary system MP:0005367 9.55 DCN SMAD3 SMAD4 TGFB1 TGFB2
9 reproductive system MP:0005389 9.43 DCN SMAD3 SMAD4 SMAD7 TGFB1 TGFB2
10 skeleton MP:0005390 9.1 DCN SMAD3 SMAD4 TGFB1 TGFB2 TGFB3

Drugs & Therapeutics for Peyronie's Disease

Drugs for Peyronie's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 2 51-84-3 187
2
Chlorhexidine Approved, Vet_approved Phase 2 55-56-1 2713 9552079
3
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
4 Peripheral Nervous System Agents Phase 2
5 abobotulinumtoxinA Phase 2
6 Botulinum Toxins Phase 2
7 Neuromuscular Agents Phase 2
8 Acetylcholine Release Inhibitors Phase 2
9 Cholinergic Agents Phase 2
10 onabotulinumtoxinA Phase 2
11 Neurotransmitter Agents Phase 2
12 Botulinum Toxins, Type A Phase 2
13 Pharmaceutical Solutions Phase 2
14 Dermatologic Agents Phase 2
15 Analgesics Phase 2
16 Disinfectants Phase 2
17 Anti-Infective Agents Phase 2
18 Chlorhexidine gluconate Phase 2
19 Anti-Infective Agents, Local Phase 2
20 Diuretics, Potassium Sparing Phase 2
21 Anesthetics Phase 2
22 Anesthetics, Local Phase 2
23 Anti-Arrhythmia Agents Phase 2
24 Sodium Channel Blockers Phase 2
25 Central Nervous System Depressants Phase 2
26
Testosterone undecanoate Approved, Investigational Phase 1 5949-44-0
27
Methyltestosterone Approved Phase 1 58-18-4 6010
28
Tocopherol Approved, Investigational Phase 1 1406-66-2 14986
29
Testosterone Approved, Investigational Phase 1 58-22-0 6013
30
Testosterone enanthate Approved Phase 1 315-37-7 9416
31
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
34 Tocotrienol Investigational Phase 1 6829-55-6
35 Tocopherols Phase 1
36 Ergocalciferols Phase 1
37 Vitamin D2 Phase 1
38 Androgens Phase 1
39 Antioxidants Phase 1
40 Calciferol Phase 1
41 Bone Density Conservation Agents Phase 1
42 Hormones Phase 1
43 Vitamins Phase 1
44 Trace Elements Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
46 Protective Agents Phase 1
47 Testosterone 17 beta-cypionate Phase 1
48 Hormone Antagonists Phase 1
49 Tocotrienols Phase 1
50 Antineoplastic Agents, Hormonal Phase 1

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Treatment Response to Xiaflex for Men With Peyronie's Disease Recruiting NCT03774264 Phase 4 Xiaflex
2 Xiaflex® Plus Testosterone Treatment Pilot Study Protocol Recruiting NCT03815331 Phase 4 Xiaflex®;Aveed
3 Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response Recruiting NCT03767452 Phase 4 Xiaflex® 0.58 mg
4 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
5 A Study of AA4500 in Men With Peyronie's Disease Completed NCT01243411 Phase 3
6 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221597 Phase 3
7 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221623 Phase 3
8 An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease Completed NCT02267460 Phase 3
9 H-22411: BOTOX® for Peyronie's Disease Unknown status NCT00812838 Phase 2 100 units of Botulinum Toxin Type A
10 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) Unknown status NCT01184586 Phase 2
11 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
12 Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
13 Urethral Sterilization With Chlorhexidine Digluconate to Facilitate Primary Repair & Same-Session Implantation Recruiting NCT03614429 Phase 2 Chlorhexidine gel will be prepared according to an international product Instillagel®
14 Intracavernosal Injection of Botulinum Toxin Type A (50 and 100 Unit) in the Treatment of Erectile Dysfunction Enrolling by invitation NCT03355963 Phase 2
15 Clostridium Histolyticum Collagenase Injection for Urethral Disease Not yet recruiting NCT02948842 Phase 2 Clostridium Histolyticum Collagenase;Lidocaine
16 Peyronie's Disease Treatment Protocol Completed NCT02072018 Phase 1 H-100;Placebo
17 Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Completed NCT01578473 Phase 1 Vitamin D2;Vitamin E;Testosterone Pellets
18 Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Completed NCT02395029 Phase 1
19 Management of Peyronie's Disease With Adipose Tissue Stem Cell Unknown status NCT02414308 Not Applicable Adipose tissue stem cell injection
20 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830 Not Applicable
21 Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease Completed NCT02298829 Subjects Previously Treated with AA4500
22 Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy Completed NCT00800813
23 Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease. Recruiting NCT03530540 Not Applicable
24 Penile Length Maintenance Post-Prostatectomy Recruiting NCT03500419 Not Applicable
25 Penile Length Restoration in Men With Diabetes Mellitus, Type II Recruiting NCT03756688 Not Applicable
26 Efficacy of Penile Traction Therapy Using a Novel Device Active, not recruiting NCT03389854 Not Applicable
27 Outcomes of Surgical Correction of Penile Curvature in Adult Not yet recruiting NCT03313986

Search NIH Clinical Center for Peyronie's Disease

Cochrane evidence based reviews: penile induration

Genetic Tests for Peyronie's Disease

Anatomical Context for Peyronie's Disease

MalaCards organs/tissues related to Peyronie's Disease:

41
Small Intestine, Bone, Lung, Endothelial, Eye, Prostate, Skin

Publications for Peyronie's Disease

Articles related to Peyronie's Disease:

(show top 50) (show all 1051)
# Title Authors Year
1
Patient's choice of health information and treatment modality for Peyronie's disease: a long-term assessment. ( 29795531 )
2018
2
Response and Rebuttal to Editorial Comment "A Comparative Study Between 2 Different Grafts Used as Patches After Plaque Incision and Inflatable Penile Prosthesis Implantation for End-Stage Peyronie's Disease". ( 29861353 )
2018
3
Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study. ( 29733116 )
2018
4
2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature. ( 29792593 )
2018
5
Contemporary Review of Peyronie's Disease Treatment. ( 29774446 )
2018
6
Surgical correction of Peyronie's disease via tunica albuginea plication: long-term follow-up. ( 29195031 )
2018
7
Grafts for Peyronie's disease: a comprehensive review. ( 29266877 )
2018
8
Prospective study to evaluate the clinical outcome of intralesional interferon-I+2b in the management of Peyronie's disease. ( 29719326 )
2018
9
Editorial Comment on "A Comparative Study Between Two Different Grafts Used as Patches After Plaque Incision and Inflatable Penile Prosthesis Implantation for End-Stage Peyronie's Disease". ( 29803354 )
2018
10
Five Things I Wish I Would Have Known Earlier in My Career: Lessons Learned in Peyronie's Disease Surgery. ( 29861359 )
2018
11
Patient's choice of health information and treatment modality for Peyronie's disease: a long term assessment. ( 29880823 )
2018
12
Characterization of Septal and Punctate Scarring in Peyronie's Disease. ( 29800632 )
2018
13
Plaque calcification: An important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie's Disease. ( 29908867 )
2018
14
A Comparative Study Between 2 Different Grafts Used as Patches After Plaque Incision and Inflatable Penile Prosthesis Implantation for End-Stage Peyronie's Disease. ( 29753801 )
2018
15
Surgical Outcomes of Plaque Excision and Grafting and Supplemental Tunica Albuginea Plication for Treatment of Peyronie's Disease With Severe Compound Curvature. ( 29802005 )
2018
16
The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronie's Disease (PD). ( 29795530 )
2018
17
Reduction in Peyronie's-like plaque size using a vacuum erection device in a rat model of Peyronie's disease via the TGF-I^/SMAD signalling pathway. ( 29806152 )
2018
18
Peyronie's disease and Dupuytren's contracture secondary to topical timolol. ( 29423783 )
2018
19
Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie's Disease. ( 29891411 )
2018
20
Collagenase clostridium histolyticum: a novel medical treatment for Peyronie's disease. ( 29761688 )
2018
21
Malleable Penile Implant Is an Effective Therapeutic Option in Men With Peyronie's Disease and Erectile Dysfunction. ( 29336942 )
2018
22
Editorial Comment on "Penile Prosthesis Implantation in Patients With Peyronie's Disease: Results of the PROPPER Study Demonstrate a Decrease In Patient-Reported Depression". ( 29803353 )
2018
23
The PICS Technique: A Novel Approach for Residual Curvature Correction During Penile Prosthesis Implantation in Patients With Severe Peyronie's Disease Using the Collagen Fleece TachoSil. ( 29325832 )
2018
24
Inflatable Penile Prosthesis Placement, Scratch Technique and Postoperative Vacuum Therapy as a Combined Approach to Definitive Treatment of Peyronie's Disease. ( 29678456 )
2018
25
Plaque Incision and Grafting for Peyronie's Disease. Dead or Alive? ( 29699751 )
2018
26
Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm Study. ( 29699756 )
2018
27
Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie's disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study. ( 29791971 )
2018
28
Increased Risk of Incident Disease in Men with Peyronie's Disease: Analysis of U.S. Claims Data. ( 29803352 )
2018
29
Devices for penile traction: the long and winding road to treating Peyronie's disease. ( 30016597 )
2018
30
Multi-institutional Prospective Analysis of Intralesional Injection of Collagenase Clostridium Histolyticum, Tunical Plication, and Partial Plaque Excision and Grafting for the Management of Peyronie's Disease. ( 30059716 )
2018
31
Penile lengthening with porcine small intestinal submucosa grafting in Peyronie's disease treatment: long-term surgical outcomes, patients' satisfaction and dissatisfaction predictors. ( 30076677 )
2018
32
A Flemish Kermis by Peeter Baltens: fashion or Peyronie's disease? ( 30094744 )
2018
33
The Effect of Adjunct Mechanical Traction on Penile Length in Men Undergoing Primary Treatment for Peyronie's Disease: A Systematic Review and Meta-analysis. ( 30099127 )
2018
34
Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie's disease. ( 30120383 )
2018
35
Intralesional and Mechanical Therapies for Peyronie's Disease: A Road Anything but Straight. ( 30177287 )
2018
36
Penile Size Restoration With Nondegloving Approach for Peyronie's Disease: Initial Experience. ( 30177471 )
2018
37
Long-term outcome after grafting with small intestinal submucosa and collagen fleece in patients with Peyronie's disease: a matched pair analysis. ( 30194372 )
2018
38
Penile Sensory Changes After Plaque Incision and Grafting Surgery for Peyronie's Disease. ( 30195564 )
2018
39
Surgical Management of Peyronie's Disease. ( 30206002 )
2018
40
Contemporary surgical and non-surgical management of Peyronie's disease. ( 30211050 )
2018
41
Xiaflex for Treatment of Peyronie's Disease. ( 30213657 )
2018
42
Re: A Worldwide Survey on Peyronie's Disease Surgical Practice Patterns among Surgeons. ( 30227551 )
2018
43
Re: Sonographic Patterns of Peyronie's Disease in Patients with Absence of Palpable Plaques. ( 30227553 )
2018
44
Re: The Extra-Tunical Grafting Procedure for Peyronie's Disease Hourglass and Indent Deformities. ( 30227571 )
2018
45
Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the Literature. ( 30237020 )
2018
46
Patient perspectives on Peyronie's disease: results of poststudy interviews from a phase 2 trial of collagenase clostridium histolyticum. ( 30237548 )
2018
47
Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis. ( 30245025 )
2018
48
Comment on "Patient perspectives on Peyronie's disease: results of poststudy interviews from a phase 2 trial of collagenase clostridium histolyticum". ( 30266972 )
2018
49
Intratunical Injection of Stromal vascular fraction prevents Fibrosis in a Rat Model of Peyronie's Disease. ( 30267556 )
2018
50
Verteporfin as a Medical Treatment in Peyronie's Disease. ( 30274909 )
2018

Variations for Peyronie's Disease

Expression for Peyronie's Disease

Search GEO for disease gene expression data for Peyronie's Disease.

Pathways for Peyronie's Disease

Pathways related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 ACTG2 CCL2 SMAD3 SMAD4 TGFB1 TGFB2
2
Show member pathways
13.6 ACTG2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
3
Show member pathways
13.59 CCL2 IFNA2 SMAD3 SMAD4 TGFB1 TGFB2
4
Show member pathways
13.46 CCL2 IFNA2 SMAD3 SMAD4 SMAD7 TGFB1
5
Show member pathways
13.3 ACTG2 CCL2 TGFB1 TGFB2 TGFB3
6
Show member pathways
13.29 ACTG2 CCL2 TGFB1 TGFB2 TGFB3
7
Show member pathways
13.26 ACTG2 CCL2 SMAD3 SMAD4 TGFB1 TGFB2
8
Show member pathways
12.99 CCL2 IFNA2 SMAD3 TGFB1 TGFB2 TGFB3
9
Show member pathways
12.97 CCL2 IFNA2 SMAD3 SMAD4 TGFB1 TGFB2
10
Show member pathways
12.84 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
11
Show member pathways
12.83 ACTG2 TGFB1 TGFB2 TGFB3
12 12.82 IFNA2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
13
Show member pathways
12.78 ACTG2 TGFB1 TGFB2 TGFB3
14
Show member pathways
12.75 SMAD3 SMAD4 SMAD7 TGFB1
15
Show member pathways
12.74 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
16
Show member pathways
12.68 DCN TGFB1 TGFB2 TGFB3
17
Show member pathways
12.6 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
18
Show member pathways
12.54 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
19
Show member pathways
12.48 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
20 12.43 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
21 12.37 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
22
Show member pathways
12.32 ACTG2 TGFB1 TGFB2 TGFB3
23
Show member pathways
12.29 SMAD3 SMAD4 SMAD7 TGFB1
24
Show member pathways
12.27 TGFB1 TGFB2 TGFB3
25
Show member pathways
12.27 SMAD3 SMAD4 SMAD7
26
Show member pathways
12.23 IFNA2 TGFB1 TGFB2 TGFB3
27 12.23 IFNA2 TGFB1 TGFB2 TGFB3
28 12.23 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
29 12.22 DCN TGFB1 TGFB2
30
Show member pathways
12.22 SMAD3 SMAD4 TGFB1 TGFB2
31
Show member pathways
12.19 TGFB1 TGFB2 TGFB3
32 12.17 SMAD3 TGFB1 TGFB2 TGFB3
33 12.16 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
34
Show member pathways
12.15 TGFB1 TGFB2 TGFB3
35 12.09 SMAD3 SMAD4 SMAD7 TGFB1
36
Show member pathways
12.06 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
37 12.03 SMAD3 SMAD4 SMAD7 TGFB1 TGFB2 TGFB3
38
Show member pathways
12.02 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
39 12.02 ACTG2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
40 11.96 SMAD3 SMAD4 TGFB1
41
Show member pathways
11.96 CCL2 SMAD3 SMAD4 SMAD7 TGFB1 TGFB2
42 11.92 SMAD3 SMAD4 TGFB1
43 11.89 CCL2 TGFB1 TGFB2 TGFB3
44 11.88 CCL2 TGFB1 TGFB2 TGFB3
45 11.87 TGFB1 TGFB2 TGFB3
46
Show member pathways
11.86 SMAD3 SMAD4 TGFB1
47
Show member pathways
11.77 SMAD3 SMAD4 TGFB1
48 11.77 SMAD3 SMAD4 SMAD7
49 11.76 SMAD3 SMAD4 SMAD7 TGFB1
50 11.75 CCL2 TGFB1 TGFB2 TGFB3

GO Terms for Peyronie's Disease

Cellular components related to Peyronie's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 CCL2 DCN IFNA2 TGFB1 TGFB2 TGFB3
2 transcription factor complex GO:0005667 9.5 SMAD3 SMAD4 SMAD7
3 extracellular space GO:0005615 9.5 ACTG2 CCL2 DCN IFNA2 TGFB1 TGFB2
4 platelet alpha granule lumen GO:0031093 9.33 TGFB1 TGFB2 TGFB3
5 SMAD protein complex GO:0071141 9.26 SMAD3 SMAD4
6 collagen-containing extracellular matrix GO:0062023 9.02 DCN IFNA2 TGFB1 TGFB2 TGFB3

Biological processes related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.95 SMAD4 TGFB1 TGFB2 TGFB3
2 protein deubiquitination GO:0016579 9.92 SMAD3 SMAD4 SMAD7
3 negative regulation of gene expression GO:0010629 9.92 IFNA2 TGFB1 TGFB2
4 response to hypoxia GO:0001666 9.91 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
5 in utero embryonic development GO:0001701 9.9 SMAD3 SMAD4 TGFB3
6 aging GO:0007568 9.89 DCN TGFB1 TGFB3
7 cell cycle arrest GO:0007050 9.88 SMAD3 TGFB1 TGFB2
8 platelet degranulation GO:0002576 9.88 TGFB1 TGFB2 TGFB3
9 negative regulation of cell growth GO:0030308 9.88 SMAD3 SMAD4 TGFB1 TGFB2
10 kidney development GO:0001822 9.87 DCN SMAD4 TGFB2
11 cellular response to transforming growth factor beta stimulus GO:0071560 9.86 SMAD3 SMAD7 TGFB1
12 cell development GO:0048468 9.86 TGFB1 TGFB2 TGFB3
13 regulation of MAPK cascade GO:0043408 9.86 TGFB1 TGFB2 TGFB3
14 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.86 SMAD3 SMAD7 TGFB1 TGFB3
15 inner ear development GO:0048839 9.85 TGFB1 TGFB2 TGFB3
16 positive regulation of cell division GO:0051781 9.84 TGFB1 TGFB2 TGFB3
17 extrinsic apoptotic signaling pathway GO:0097191 9.83 SMAD3 TGFB1 TGFB2
18 ureteric bud development GO:0001657 9.83 SMAD3 SMAD7 TGFB1
19 positive regulation of protein secretion GO:0050714 9.83 TGFB1 TGFB2 TGFB3
20 ventricular septum morphogenesis GO:0060412 9.82 SMAD4 SMAD7 TGFB2
21 response to progesterone GO:0032570 9.8 TGFB1 TGFB2 TGFB3
22 positive regulation of bone mineralization GO:0030501 9.8 SMAD3 TGFB1 TGFB3
23 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.8 SMAD4 TGFB1 TGFB2 TGFB3
24 endoderm development GO:0007492 9.77 SMAD3 SMAD4 TGFB1
25 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.77 SMAD3 TGFB1 TGFB2
26 wound healing GO:0042060 9.77 DCN SMAD3 TGFB1 TGFB2 TGFB3
27 secondary palate development GO:0062009 9.75 SMAD4 TGFB2 TGFB3
28 epithelial to mesenchymal transition GO:0001837 9.74 TGFB1 TGFB2
29 protein kinase B signaling GO:0043491 9.74 CCL2 TGFB1
30 gastrulation GO:0007369 9.74 SMAD3 SMAD4
31 pathway-restricted SMAD protein phosphorylation GO:0060389 9.74 SMAD7 TGFB1 TGFB2
32 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 CCL2 TGFB1
33 mammary gland development GO:0030879 9.73 TGFB1 TGFB3
34 negative regulation of mitotic cell cycle GO:0045930 9.73 SMAD3 TGFB1
35 digestive tract development GO:0048565 9.73 TGFB1 TGFB3
36 odontogenesis GO:0042476 9.73 TGFB2 TGFB3
37 positive regulation of protein import into nucleus GO:0042307 9.73 SMAD3 TGFB1
38 face morphogenesis GO:0060325 9.72 TGFB1 TGFB3
39 developmental growth GO:0048589 9.72 SMAD3 SMAD4
40 outflow tract septum morphogenesis GO:0003148 9.72 SMAD4 TGFB2
41 positive regulation of collagen biosynthetic process GO:0032967 9.72 TGFB1 TGFB3
42 positive regulation of SMAD protein signal transduction GO:0060391 9.72 SMAD4 TGFB1 TGFB3
43 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.71 SMAD7 TGFB1
44 uterus development GO:0060065 9.71 SMAD4 TGFB2
45 negative regulation of immune response GO:0050777 9.71 TGFB1 TGFB2
46 salivary gland morphogenesis GO:0007435 9.71 TGFB1 TGFB2 TGFB3
47 lens fiber cell differentiation GO:0070306 9.7 SMAD3 TGFB1
48 heart valve morphogenesis GO:0003179 9.7 TGFB1 TGFB2
49 response to laminar fluid shear stress GO:0034616 9.7 SMAD7 TGFB1 TGFB3
50 positive regulation of extracellular matrix assembly GO:1901203 9.69 SMAD3 TGFB1

Molecular functions related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.8 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
2 cytokine activity GO:0005125 9.72 CCL2 IFNA2 TGFB1 TGFB2 TGFB3
3 transcription regulatory region DNA binding GO:0044212 9.69 SMAD3 SMAD4 SMAD7
4 growth factor activity GO:0008083 9.63 TGFB1 TGFB2 TGFB3
5 collagen binding GO:0005518 9.56 DCN SMAD3 SMAD4 SMAD7
6 type I transforming growth factor beta receptor binding GO:0034713 9.54 SMAD7 TGFB1 TGFB3
7 proximal promoter sequence-specific DNA binding GO:0000987 9.49 SMAD3 SMAD4
8 R-SMAD binding GO:0070412 9.48 SMAD3 SMAD4
9 I-SMAD binding GO:0070411 9.43 SMAD4 SMAD7
10 type II transforming growth factor beta receptor binding GO:0005114 9.33 TGFB1 TGFB2 TGFB3
11 transforming growth factor beta receptor binding GO:0005160 9.26 SMAD3 TGFB1 TGFB2 TGFB3
12 type III transforming growth factor beta receptor binding GO:0034714 8.8 TGFB1 TGFB2 TGFB3

Sources for Peyronie's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....